

Julien Taieb

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7159848/publications.pdf>

Version: 2024-02-01

287
papers

16,139
citations

19608

61
h-index

19136

118
g-index

310
all docs

310
docs citations

310
times ranked

20755
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognosis and chemosensitivity of non-colorectal alimentary tract cancers with microsatellite instability. <i>Digestive and Liver Disease</i> , 2023, 55, 123-130.	0.4	3
2	Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. <i>Journal of the National Cancer Institute</i> , 2022, 114, 60-67.	3.0	5
3	The "Immunescore" in rectal cancer: could we search quality beyond quantity of life?. <i>Oncotarget</i> , 2022, 13, 18-31.	0.8	3
4	Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. <i>Journal of the National Cancer Institute</i> , 2022, 114, 819-828.	3.0	2
5	Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials. <i>British Journal of Cancer</i> , 2022, 126, 440-448.	2.9	15
6	Upfront progression under pembrolizumab followed by a complete response after encorafenib and cetuximab treatment in BRAF V600E mutated and microsatellite unstable metastatic colorectal cancer patient: A case report. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 114-118.	1.5	4
7	Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies. <i>European Journal of Cancer</i> , 2022, 162, 138-147.	1.3	4
8	Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study. <i>British Journal of Cancer</i> , 2022, 126, 1394-1400.	2.9	5
9	Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49. <i>Digestive and Liver Disease</i> , 2022, 54, 324-330.	0.4	5
10	Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer. <i>Cancers</i> , 2022, 14, 406.	1.7	11
11	Prognostic impact of early treatment discontinuation and early oxaliplatin discontinuation in patients treated with 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: an ACCENT/IDEA pooled analysis of 11 trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 11-11.	0.8	6
12	Circulating tumor DNA (ctDNA) in adjuvant therapy of early stage colon cancer: current status and future perspectives. <i>Acta Oncologica</i> , 2022, 61, 523-530.	0.8	5
13	BRCA1 and RAD51C promotor methylation in human resectable pancreatic adenocarcinoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101880.	0.7	1
14	Overall Survival and Prognostic Factors among Older Patients with Metastatic Pancreatic Cancer: A Retrospective Analysis Using a Hospital Database. <i>Cancers</i> , 2022, 14, 1105.	1.7	2
15	Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study". <i>Clinical Colorectal Cancer</i> , 2022, 21, 132-140.	1.0	5
16	Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors. <i>JCO Precision Oncology</i> , 2022, 6, e2100181.	1.5	33
17	Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma. <i>Oncologist</i> , 2022, , .	1.9	2
18	Pathological complete response of liver metastases of cholangiocarcinoma using hepatic intra-arterial gemcitabine-oxaliplatin. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, , 101920.	0.7	1

#	ARTICLE	IF	CITATIONS
19	Impact of diabetes and metformin use on recurrence and outcome in stage II–III colon cancer patients—A pooled analysis of three adjuvant trials. <i>European Journal of Cancer</i> , 2022, 166, 100-111.	1.3	13
20	Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series. <i>European Journal of Cancer</i> , 2022, 168, 34-40.	1.3	4
21	MSI colorectal cancer, all you need to know. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101983.	0.7	8
22	<sc>FOLFIRI</sc> plus <sc>BEvacizumab</sc> or <sc>aFLbercept</sc> after <sc>FOLFOX</sc>—bevacizumab failure for <sc>COlorectal</sc> cancer (<sc>BEFLICO</sc>): An <sc>AGEO</sc> multicenter study. <i>International Journal of Cancer</i> , 2022, 151, 1978-1988.	2.3	5
23	Phase III study (daNIS-2) of the anti-TGF- β 2 monoclonal antibody (mAb) NIS793 with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4193-TPS4193.	0.8	3
24	Bridge to surgery after irinotecan-based liver chemoembolization for metastatic gastric adenocarcinoma: Letter to the editor. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101557.	0.7	0
25	Efficacy of Anti-EGFR in Microsatellite Instability Metastatic Colorectal Cancer Depending on Sporadic or Familial Origin. <i>Journal of the National Cancer Institute</i> , 2021, 113, 496-500.	3.0	5
26	Clinical and Regulatory Considerations for the Use of Bevacizumab Biosimilars in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, 20, 42-51.e3.	1.0	6
27	The CIREL Cohort: A Prospective Controlled Registry Studying the Real-Life Use of Irinotecan-Loaded Chemoembolisation in Colorectal Cancer Liver Metastases: Interim Analysis. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 50-62.	0.9	18
28	A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency. <i>Cancer Discovery</i> , 2021, 11, 408-423.	7.7	28
29	Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. <i>Journal of Clinical Oncology</i> , 2021, 39, 966-977.	0.8	122
30	What is the Best Therapeutic Strategy for Metachronous Resectable Colorectal Liver Metastases After Adjuvant Oxaliplatin-Based Chemotherapy? A Multidisciplinary Inter-Group Survey. <i>World Journal of Surgery</i> , 2021, 45, 822-830.	0.8	3
31	Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials. <i>European Journal of Cancer</i> , 2021, 144, 101-112.	1.3	18
32	Impact of the IDEA Collaboration Study Results on Clinical Practice in France for Patients With Stage III Colon Cancer: A National GERCOR - PRODIGE Survey. <i>Clinical Colorectal Cancer</i> , 2021, 20, 79-83.e4.	1.0	4
33	Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34,640 Patients in the ACCENT Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 400-407.	3.0	44
34	Real-world study of treatment patterns and outcomes among patients with metastatic pancreatic ductal adenocarcinoma (PDAC) in Europe.. <i>Journal of Clinical Oncology</i> , 2021, 39, 391-391.	0.8	0
35	Prognostic value of the PrP ^C -ILK-IDO1 axis in the mesenchymal colorectal cancer subtype. <i>Oncolmmunology</i> , 2021, 10, 1940674.	2.1	11
36	Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. <i>Journal of Clinical Oncology</i> , 2021, 39, 642-651.	0.8	84

#	ARTICLE	IF	CITATIONS
37	Comments On "A Prospective, Single-Arm, Multicenter Trial of Diverting Stoma Followed By Neoadjuvant Chemotherapy Using mFOLFOX6 for Obstructive Colon Cancer: YCOG 1305 (PROBE study)" Ann Surg 2020 [Epub ahead of print]. DOI: 10.1097/SLA.0000000000004494. Annals of Surgery, 2021, 274, e878-e879.	2.1	0
38	Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial. Digestive and Liver Disease, 2021, 53, 318-323.	0.4	14
39	Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk Stage II and III colon cancers? Three years' follow-up results of the PRODIGE 22 phase II randomized multicentre trial. Colorectal Disease, 2021, 23, 1357-1369.	0.7	23
40	Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort. British Journal of Cancer, 2021, 124, 1941-1948.	2.9	20
41	Acute renal failure under encorafenib, binimetinib and cetuximab for BRAF V600E-mutated colorectal cancer. European Journal of Cancer, 2021, 147, 60-62.	1.3	2
42	Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database. Future Oncology, 2021, 17, 1483-1494.	1.1	7
43	Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: A bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101681.	0.7	4
44	Characterization of Plasma Cell-Free DNA Integrity Using Droplet-Based Digital PCR: Toward the Development of Circulating Tumor DNA-Dedicated Assays. Frontiers in Oncology, 2021, 11, 639675.	1.3	3
45	Relationships Between KRAS Category/Baseline Tumor Load and Early Tumor Shrinkage, Depth of Response, and Outcomes in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2021, , .	1.0	1
46	Chart review of diagnostic methods, baseline characteristics and symptoms for European patients with pancreatic cancer. Future Oncology, 2021, 17, 1843-1854.	1.1	4
47	Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma. Clinical Therapeutics, 2021, 43, 1201-1212.	1.1	4
48	Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial. Clinical Cancer Research, 2021, 27, 5638-5646.	3.2	42
49	Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design. Future Oncology, 2021, 17, 1977-1985.	1.1	24
50	Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study. Cancers, 2021, 13, 2797.	1.7	11
51	Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer. Clinical Cancer Research, 2021, 27, 4768-4780.	3.2	25
52	Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors. Cancers, 2021, 13, 3776.	1.7	5
53	Treatment with encorafenib and cetuximab of a non-anti-epidermal growth factor receptor-naive patient for BRAF V600E-mutated metastatic colon cancer. European Journal of Cancer, 2021, 152, 1-3.	1.3	2
54	First-line chemotherapy with raltitrexid in metastatic colorectal cancer: an Association des Gastro-entérologues Oncologues (AGEO) multicentre study. Digestive and Liver Disease, 2021, , .	0.4	3

#	ARTICLE	IF	CITATIONS
55	Impact of laparoscopy on oncological outcomes after colectomy for stage III colon cancer: A post-hoc multivariate analysis from PETACC8 European randomized clinical trial. <i>Digestive and Liver Disease</i> , 2021, 53, 1034-1040.	0.4	3
56	Predictive factors of severe early treatment-related toxicity in patients receiving first-line treatment for metastatic colorectal cancer: Pooled analysis of 2190 patients enrolled in FAVORATION Francophone de Cancérologie Digestive (FFCD) trials. <i>European Journal of Cancer</i> , 2021, 153, 40-50.	1.3	2
57	How I treat stage II colon cancer patients. <i>ESMO Open</i> , 2021, 6, 100184.	2.0	14
58	Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1693-1704.	3.0	25
59	Chemotherapy use in end-of-life digestive cancer patients: a retrospective AGEO observational study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101709.	0.7	1
60	Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives. <i>Cancers</i> , 2021, 13, 4743.	1.7	8
61	Atypical cutaneous metastases of poorly cohesive carcinoma of the stomach: Letter to the editor. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 46, 101795.	0.7	0
62	Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial. <i>Digestive and Liver Disease</i> , 2021, 53, 1254-1259.	0.4	5
63	Skeletal muscle loss during chemotherapy and its association with survival and systemic treatment toxicity in metastatic colorectal cancer: An AGEO prospective multicenter study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101603.	0.7	12
64	Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS). <i>European Journal of Cancer</i> , 2021, 159, 24-33.	1.3	24
65	Targeting HGF/c-Met Axis Decreases Circulating Regulatory T Cells Accumulation in Gastric Cancer Patients. <i>Cancers</i> , 2021, 13, 5562.	1.7	6
66	Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin. <i>Journal of Clinical Oncology</i> , 2021, 39, 4009-4019.	0.8	45
67	Next-Generation Sequencing Targeted Panel in Routine Care for Metastatic Colon Cancers. <i>Cancers</i> , 2021, 13, 5750.	1.7	4
68	Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003. <i>Future Oncology</i> , 2021, 17, 5013-5022.	1.1	2
69	Biomarkers for Immunotherapy in Gastrointestinal Cancers. , 2021, , 273-296.		0
70	Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab. <i>Gut</i> , 2020, 69, 531-539.	6.1	97
71	Integration of elicited expert information via a power prior in Bayesian variable selection: Application to colon cancer data. <i>Statistical Methods in Medical Research</i> , 2020, 29, 541-567.	0.7	8
72	Evaluation of the prognostic impact of pathologic response to preoperative chemotherapy using Mandâ€™s Tumor Regression Grade (TRG) in gastric adenocarcinoma. <i>Digestive and Liver Disease</i> , 2020, 52, 107-114.	0.4	24

#	ARTICLE	IF	CITATIONS
73	Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 295-301.	0.7	13
74	Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance. <i>Gastric Cancer</i> , 2020, 23, 73-81.	2.7	75
75	Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study. <i>Clinical Colorectal Cancer</i> , 2020, 19, 39-47.e5.	1.0	9
76	Plasma clearance of <i>RAS</i> mutation under therapeutic pressure is a rare event in metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2020, 147, 1185-1189.	2.3	26
77	YpN0 rectal cancer patients with sterilized lymph nodes after neoadjuvant chemoradiotherapy are of greater risk of recurrence. <i>Digestive and Liver Disease</i> , 2020, 52, 214-220.	0.4	3
78	High IGF1R protein expression correlates with disease-free survival of patients with stage III colon cancer. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 237-247.	2.1	3
79	Factors associated with anal cancer screening uptake in men who have sex with men living with HIV: a cross-sectional study. <i>European Journal of Cancer Prevention</i> , 2020, 29, 1-6.	0.6	5
80	Immune scores in colorectal cancer: Where are we?. <i>European Journal of Cancer</i> , 2020, 140, 105-118.	1.3	50
81	Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf <i>Lancet Oncology</i> , The, 2020, 21, 1620-1629.	5.1	152
82	The consensus Immunoscore in phase 3 clinical trials; potential impact on patient management decisions. <i>OncImmunology</i> , 2020, 9, 1812221.	2.1	15
83	Adjuvant Chemotherapy for Stage III Colon Cancer. <i>Cancers</i> , 2020, 12, 2679.	1.7	44
84	Scientific Societies Should Start Sponsoring Observational Studies. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 1865-1867.	0.9	3
85	Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097535.	1.4	24
86	Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA: The CIRCULATE-PRODIGE 70 trial. <i>Digestive and Liver Disease</i> , 2020, 52, 730-733.	0.4	18
87	Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302). <i>Clinical Colorectal Cancer</i> , 2020, 19, 285-290.	1.0	5
88	A comprehensive overview of promising biomarkers in stage II colorectal cancer. <i>Cancer Treatment Reviews</i> , 2020, 88, 102059.	3.4	12
89	Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study. <i>ESMO Open</i> , 2020, 5, e000698.	2.0	26
90	Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study. <i>British Journal of Cancer</i> , 2020, 123, 518-524.	2.9	16

#	ARTICLE	IF	CITATIONS
91	Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study. <i>Gut</i> , 2020, 69, 681-690.	6.1	79
92	Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR). <i>Journal of Clinical Oncology</i> , 2020, 38, 1702-1710.	0.8	40
93	Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials. <i>JCO Precision Oncology</i> , 2020, 4, 116-127.	1.5	4
94	A multicentre, international, observational study on transarterial chemoembolisation in colorectal cancer liver metastases: Design and rationale of CIREL. <i>Digestive and Liver Disease</i> , 2020, 52, 857-861.	0.4	4
95	A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency. <i>British Journal of Cancer</i> , 2020, 123, 811-818.	2.9	39
96	Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX). <i>European Journal of Cancer</i> , 2020, 136, 25-34.	1.3	6
97	Does Bead Size Affect Patient Outcome in Irinotecan-Loaded Beads Chemoembolization Plus Systemic Chemotherapy Regimens for Liver-Dominant Colorectal Cancer? Results of an Observational Study. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 866-874.	0.9	13
98	Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives. <i>Drugs</i> , 2020, 80, 401-415.	4.9	42
99	Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial. <i>British Journal of Cancer</i> , 2020, 122, 957-962.	2.9	4
100	Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study. <i>International Journal of Cancer</i> , 2020, 147, 285-296.	2.3	56
101	First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study. <i>ESMO Open</i> , 2020, 5, e000587.	2.0	43
102	The area between ROC curves, a non-parametric method to evaluate a biomarker for patient treatment selection. <i>Biometrical Journal</i> , 2020, 62, 1476-1493.	0.6	4
103	Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. <i>European Journal of Cancer</i> , 2020, 130, 63-71.	1.3	15
104	Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27). <i>Clinical Colorectal Cancer</i> , 2020, 19, 301-310.e1.	1.0	9
105	Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review. <i>Cancer Treatment Reviews</i> , 2020, 87, 102028.	3.4	9
106	Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy – a randomized phase II study – SULTAN UCGI 30/PRODIGE 53 (NCT03164655)- study protocol. <i>BMC Cancer</i> , 2020, 20, 74.	1.1	9
107	Clinicopathological and molecular biological characteristics of early-onset stage II/III colorectal adenocarcinoma: An analysis of 25 studies with 47,184 patients (pts) in the adjuvant colon cancer end points (ACCENT) database.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4099-4099.	0.8	1
108	Bidirectional chemotherapy combining intraperitoneal docetaxel with intravenous 5-fluorouracil and oxaliplatin for patients with unresectable peritoneal metastasis from gastric cancer: the first study in Western countries. <i>Pleura and Peritoneum</i> , 2020, 5, 20190035.	0.5	1

#	ARTICLE	IF	CITATIONS
109	The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer. <i>EBioMedicine</i> , 2019, 46, 94-104.	2.7	24
110	Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial. <i>Cancer Medicine</i> , 2019, 8, 5079-5088.	1.3	11
111	Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial. <i>British Journal of Cancer</i> , 2019, 121, 312-317.	2.9	17
112	BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study. <i>Cancers</i> , 2019, 11, 998.	1.7	22
113	The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer. <i>Drugs</i> , 2019, 79, 1375-1394.	4.9	48
114	Exploring the best treatment options for BRAF-mutant metastatic colon cancer. <i>British Journal of Cancer</i> , 2019, 121, 434-442.	2.9	54
115	Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies. <i>Annals of Oncology</i> , 2019, 30, 1466-1471.	0.6	97
116	Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Post hoc Analysis of the MOSAIC and PETACC-8 Trials. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1153-1161.	1.1	14
117	Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481987866.	1.4	39
118	Hereditary gastrointestinal cancers: why genetic counseling matters. <i>Annals of Oncology</i> , 2019, 30, 1535-1536.	0.6	0
119	Evaluation of two nutritional scores' association with systemic treatment toxicity and survival in metastatic colorectal cancer: an AGEO prospective multicentre study. <i>European Journal of Cancer</i> , 2019, 119, 35-43.	1.3	24
120	Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials. <i>Clinical Colorectal Cancer</i> , 2019, 18, 245-256.e5.	1.0	2
121	Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 420-435.	5.1	191
122	FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial. <i>European Journal of Cancer</i> , 2019, 115, 97-106.	1.3	29
123	Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohort. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, 663-668.	0.7	12
124	How best to treat older patients with metastatic colorectal cancer?. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 331-333.	3.7	7
125	Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study. <i>British Journal of Cancer</i> , 2019, 120, 697-702.	2.9	19
126	How to better select patients with advanced gastric cancer for immunotherapy. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 6-6.	1.5	8

#	ARTICLE	IF	CITATIONS
127	Refining adjuvant therapy for non-metastatic colon cancer, new standards and perspectives. <i>Cancer Treatment Reviews</i> , 2019, 75, 1-11.	3.4	53
128	How I treat pancreatic cancer. <i>ESMO Open</i> , 2019, 4, e000818.	2.0	11
129	Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4) Tj ETQq1 100784314ngBT /O	1.0	7
130	Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design. <i>Future Oncology</i> , 2019, 15, 567-577.	1.1	20
131	How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric Cohort. <i>Annals of Surgical Oncology</i> , 2019, 26, 109-117.	0.7	64
132	Relative contribution of clinical and molecular features to outcome within low and high risk T and N groups in stage III colon cancer (CC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3520-3520.	0.8	4
133	Methylated circulating tumor DNA (Met-DNA) as an independent prognostic factor in metastatic pancreatic adenocarcinoma (mPAC) patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4136-4136.	0.8	3
134	Ampullary carcinoma prognostic markers. <i>Oncotarget</i> , 2019, 10, 4509-4510.	0.8	0
135	Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study). <i>Digestive and Liver Disease</i> , 2018, 50, 408-410.	0.4	14
136	Role of circulating tumor DNA in the management of patients with colorectal cancer. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018, 42, 396-402.	0.7	14
137	Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK). <i>Digestive and Liver Disease</i> , 2018, 50, 305-307.	0.4	13
138	Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers. <i>Future Oncology</i> , 2018, 14, 1629-1645.	1.1	22
139	Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 1177-1188.	13.9	699
140	Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 321-335.	1.2	27
141	Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study. <i>Targeted Oncology</i> , 2018, 13, 107-112.	1.7	8
142	Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy. <i>JAMA Oncology</i> , 2018, 4, 379.	3.4	104
143	Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to KÀrhne Prognostic Category and BRAF Mutation Status. <i>Clinical Colorectal Cancer</i> , 2018, 17, 50-57.e8.	1.0	6
144	5-FU or mitomycin C hepatic arterial infusion after failure of arterial oxaliplatin in patients with colorectal cancer unresectable liver metastases. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018, 42, 255-260.	0.7	7

#	ARTICLE	IF	CITATIONS
145	Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With <i>RAS</i> and <i>BRAF</i> Mutational Status. <i>JAMA Oncology</i> , 2018, 4, e173695.	3.4	55
146	Reply to M. Mo et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 2452-2453.	0.8	0
147	Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1469-1477.	0.8	122
148	Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9). <i>Journal of Clinical Oncology</i> , 2018, 36, 674-681.	0.8	70
149	Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE). <i>TJ ETQq1</i> 1 0.784314 rgBT /Overlo	0.4	104
150	Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer. <i>ESMO Open</i> , 2018, 3, e000353.	2.0	38
151	Colorectal Cancer: Why Does Side Matter?. <i>Drugs</i> , 2018, 78, 789-798.	4.9	41
152	Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 1094-1106.	5.1	108
153	Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy. <i>Clinical Cancer Research</i> , 2018, 24, 4745-4753.	3.2	23
154	Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with <i>RAS</i> wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials. <i>British Journal of Cancer</i> , 2018, 119, 303-312.	2.9	29
155	Beyond Primary Tumor Location and <i>RAS/BRAF</i> Mutational Status as Prognostic Factor in Stage III Colon Cancer—Reply. <i>JAMA Oncology</i> , 2018, 4, 1298.	3.4	9
156	Comparison of anal cancer screening strategies including standard anoscopy, anal cytology, and HPV genotyping in HIV-positive men who have sex with men. <i>British Journal of Cancer</i> , 2018, 119, 381-386.	2.9	34
157	Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives. <i>Cancer Treatment Reviews</i> , 2018, 66, 104-113.	3.4	78
158	Deep Learning and Radiomics predict complete response after neo-adjuvant chemoradiation for locally advanced rectal cancer. <i>Scientific Reports</i> , 2018, 8, 12611.	1.6	142
159	Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. <i>Clinical Colorectal Cancer</i> , 2018, 17, e617-e629.	1.0	54
160	Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study. <i>British Journal of Cancer</i> , 2018, 119, 424-428.	2.9	22
161	Gemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracil plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): A randomized phase II study (PRODIGE 37-FIRGEMAX).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4107-4107.	0.8	7
162	Quality of life at baseline in the international open-label early-access program of trifluridine/tipiracil in previously treated metastatic colorectal cancer (phase IIIb).. <i>Journal of Clinical Oncology</i> , 2018, 36, 803-803.	0.8	3

#	ARTICLE	IF	CITATIONS
163	JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1) maintenance therapy versus continuation of first-line chemotherapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC).. Journal of Clinical Oncology, 2018, 36, TPS195-TPS195.	0.8	12
164	Baseline characteristics in the international, open-label, early-access program of trifluridine/tipiracil in previously treated metastatic colorectal cancer (phase IIIb).. Journal of Clinical Oncology, 2018, 36, 761-761.	0.8	1
165	Three fluoropyrimidine-based regimens in second-line therapy following nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer: Efficacy and tolerance in clinical practice.. Journal of Clinical Oncology, 2018, 36, 370-370.	0.8	0
166	Immunomodulatory Activity of VEGF in Cancer. International Review of Cell and Molecular Biology, 2017, 330, 295-342.	1.6	153
167	Outcomes in elderly patients admitted to the intensive care unit with solid tumors. Annals of Intensive Care, 2017, 7, 26.	2.2	40
168	Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial. The Lancet Gastroenterology and Hepatology, 2017, 2, 337-346.	3.7	28
169	Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects. European Journal of Cancer, 2017, 79, 15-22.	1.3	42
170	Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer. Journal of the National Cancer Institute, 2017, 109, djw272.	3.0	201
171	Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncology, The, 2017, 18, 1624-1636.	5.1	595
172	Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228). British Journal of Cancer, 2017, 117, 965-973.	2.9	18
173	First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncology, The, 2017, 18, 1159-1171.	5.1	293
174	Adequate SIRT activity dose is as important as adequate chemotherapy dose – Authors' reply. Lancet Oncology, The, 2017, 18, e637.	5.1	2
175	Safety and efficacy of intra-arterial hepatic chemotherapy with doxorubicin-loaded nanoparticles in hepatocellular carcinoma. ESMO Open, 2017, 2, e000238.	2.0	37
176	Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. European Journal of Cancer, 2017, 82, 16-24.	1.3	40
177	Immune therapy in colorectal cancer. Colorectal Cancer, 2017, 6, 1-10.	0.8	3
178	Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study). Clinical Cancer Research, 2017, 23, 5416-5425.	3.2	189
179	Impact of primary tumour location on response and resection outcomes in patients with metastatic colorectal cancer (mCRC) undergoing first-line treatment. Annals of Oncology, 2017, 28, iii113-iii114.	0.6	2
180	Clinical utility of colon cancer molecular subtypes: Validation of two main colorectal molecular classifications on the PETACC-8 phase III trial cohort.. Journal of Clinical Oncology, 2017, 35, 3509-3509.	0.8	24

#	ARTICLE	IF	CITATIONS
181	Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status.. Journal of Clinical Oncology, 2017, 35, 3515-3515.	0.8	3
182	Colorectal cancer (CRC) patients surveyed by 18FDGPET-CT (PET-CT): An open-label multicenter randomized trial (NCT 00624260).. Journal of Clinical Oncology, 2017, 35, 3520-3520.	0.8	2
183	Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study. Oncotarget, 2017, 8, 101383-101393.	0.8	31
184	Vitamin K epoxide reductase complex subunit 1 (VKORC1): A pharmacogenomic predictor of response and survival in patients (pts) on triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-Cet) for initially unresectable liver metastases from colorectal cancer (uLM-CRC) (EU trial) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 612	0.8	0
185	Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a multicentric study. BMC Cancer, 2016, 16, 823.	1.1	25
186	Checkpoint inhibitors and gastrointestinal immune-related adverse events. Current Opinion in Oncology, 2016, 28, 264-268.	1.1	35
187	Reply to the comment on "Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after FOLFIRINOX failure: an AGEO prospective multicentre cohort"™. British Journal of Cancer, 2016, 114, e9-e9.	2.9	3
188	FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncology, The, 2016, 17, 801-810.	5.1	719
189	Advances in management of adjuvant chemotherapy in rectal cancer: Consequences for clinical practice. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 546-552.	0.7	9
190	Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer. European Journal of Cancer, 2016, 68, 163-172.	1.3	8
191	Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study. Digestive and Liver Disease, 2016, 48, 441-445.	0.4	17
192	<i>DPYD</i> Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer. JAMA Oncology, 2016, 2, 655.	3.4	62
193	Prognostic Effect of <i>BRAF</i> and <i>KRAS</i> Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab. JAMA Oncology, 2016, 2, 643.	3.4	125
194	Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients. Oncologist, 2016, 21, 292-300.	1.9	40
195	Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer. Clinical Colorectal Cancer, 2016, 15, 250-256.	1.0	12
196	Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study. Journal of the National Cancer Institute, 2016, 108, djv438.	3.0	127
197	Advanced small bowel adenocarcinoma: Molecular characteristics and therapeutic perspectives. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 154-160.	0.7	33
198	Methylator phenotype in colorectal cancer: A prognostic factor or not?. Critical Reviews in Oncology/Hematology, 2016, 99, 74-80.	2.0	39

#	ARTICLE	IF	CITATIONS
199	Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology. <i>Quality of Life Research</i> , 2016, 25, 1713-1723.	1.5	28
200	Validation of the prognostic impact of lymphocyte infiltration (LI) in patients (pts) with stage III colon cancer (CC) treated with adjuvant FOLFOX+/- cetuximab: A PETACC8 translational study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 553-553.	0.8	3
201	Unresectable liver metastases in colorectal cancer: review of current strategies. <i>Minerva Chirurgica</i> , 2016, 71, 382-397.	0.8	1
202	Secondâ€line chemotherapy for advanced biliary tract cancer after failure of the gemcitabineâ€platinum combination: A large multicenter study by the Association des Gastroâ€ntâ€rologues Oncologues. <i>Cancer</i> , 2015, 121, 3290-3297.	2.0	95
203	Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge. <i>World Journal of Gastroenterology</i> , 2015, 21, 11428.	1.4	226
204	Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial. <i>PLoS ONE</i> , 2015, 10, e0125350.	1.1	7
205	VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. <i>Journal of Experimental Medicine</i> , 2015, 212, 139-148.	4.2	836
206	FOLFIRINOX for Locally Advanced Pancreatic Adenocarcinoma: Results of an AGEO Multicenter Prospective Observational Cohort. <i>Annals of Surgical Oncology</i> , 2015, 22, 295-301.	0.7	145
207	FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9 â€“ FFCD 0802). <i>Digestive and Liver Disease</i> , 2015, 47, 271-272.	0.4	13
208	Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. <i>British Journal of Cancer</i> , 2015, 113, 989-995.	2.9	151
209	Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort. <i>Annals of Surgical Oncology</i> , 2015, 22, 1196-1205.	0.7	70
210	Complete pathological response of unresectable liver metastases from colorectal cancer after trans-arterial chemoembolization with drug-eluting beads loaded with irinotecan (DEBIRI) and concomitant systemic FOLFOX: A case report from the FFCD 1201 trial. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, e73-e77.	0.7	13
211	Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial â€“ the PRODIGE 22 - ECKINOXE trial. <i>BMC Cancer</i> , 2015, 15, 511.	1.1	43
212	Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III colon cancers from patients (pts) treated with adjuvant FOLFOX +/- cetuximab in the PETACC8 and NCCTG N0147 adjuvant trials.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3506-3506.	0.8	2
213	Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX+/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3507-3507.	0.8	6
214	Masitinib plus FOLFIRI for second line treatment of metastatic colorectal cancer: An open label phase Ib/II trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3526-3526.	0.8	4
215	Masitinib plus irinotecan for second line treatment of esophagogastric adenocarcinoma: An open label phase Ib/II trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4027-4027.	0.8	1
216	Nab paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after failure of folfirinox: Results of an AGEO multicenter prospective cohort.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4123-4123.	0.8	6

#	ARTICLE	IF	CITATIONS
235	Double pancreatic and gastric adenocarcinomas: A rare association. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013, 37, e137-e140.	0.7	7
236	Digestive neuroendocrine tumors (DNET): The era of targeted therapies. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013, 37, 134-141.	0.7	4
237	The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 261-269.	1.0	94
238	Mucosal Imprinting of Vaccine-Induced CD8 ⁺ T Cells Is Crucial to Inhibit the Growth of Mucosal Tumors. <i>Science Translational Medicine</i> , 2013, 5, 172ra20.	5.8	195
239	An unusual recurrence site for HCC!. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013, 37, e29-e31.	0.7	0
240	Colon Cancer Mutation: Prognosis/Prediction Letter. <i>Clinical Cancer Research</i> , 2013, 19, 1300-1300.	3.2	4
241	Folfirinox for Locally Advanced Pancreatic Adenocarcinoma. Results of an Ageo Multicenter Prospective Study. <i>Annals of Oncology</i> , 2013, 24, iv12.	0.6	3
242	Therapeutic implications of DNA mismatch repair in adjuvant colorectal cancer chemotherapy. <i>Colorectal Cancer</i> , 2013, 2, 51-59.	0.8	1
243	VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer. <i>Cancer Research</i> , 2013, 73, 539-549.	0.4	528
244	VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer. <i>Oncolmmunology</i> , 2013, 2, e25156.	2.1	32
245	Subgroup analyses results of the PETACC8 phase III trial comparing adjuvant FOLFOX4 with or without cetuximab (CTX) in resected stage III colon cancer (CC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 3525-3525.	0.8	13
246	Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. <i>Oncolmmunology</i> , 2012, 1, 326-333.	2.1	95
247	Cost-effectiveness modeling of colorectal cancer: Computed tomography colonography vs colonoscopy or fecal occult blood tests. <i>European Journal of Radiology</i> , 2012, 81, 1413-1419.	1.2	11
248	O-0028 Adjuvant Folfox4 +/- Cetuximab in KRAS Wild-Type Patients with Resected Stage III Colon Cancer Results from the Petacc8 Intergroup Trial. <i>Annals of Oncology</i> , 2012, 23, iv17.	0.6	6
249	Cetuximab combined with infusional 5-fluorouracil/folinic acid (5-FU/FA) and oxaliplatin in metastatic colorectal cancer (mCRC): A pooled analysis of COIN and OPUS study data.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3574-3574.	0.8	6
250	Medical treatment of pancreatic cancer: New hopes after 10years of gemcitabine. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 364-374.	0.7	13
251	Serum Apolipoproteins C-I and C-III Are Reduced in Stomach Cancer Patients: Results from MALDI-Based Peptidome and Immuno-Based Clinical Assays. <i>PLoS ONE</i> , 2011, 6, e14540.	1.1	43
252	Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy. <i>Cancer</i> , 2011, 117, 1422-1428.	2.0	71

#	ARTICLE	IF	CITATIONS
253	Nutritional Status Affects Treatment Tolerability and Survival in Metastatic Colorectal Cancer Patients: Results of an AGEO Prospective Multicenter Study. <i>Oncology</i> , 2011, 81, 395-402.	0.9	80
254	Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy. <i>Clinical Cancer Research</i> , 2011, 17, 7470-7478.	3.2	76
255	Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2011, 17, 2255.	1.4	18
256	Natural Killer Cell IFN- γ Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor-Bearing Patients. <i>Cancer Research</i> , 2009, 69, 3563-3569.	0.4	181
257	Incidence of KRAS status in ongoing adjuvant trials in colon cancer. <i>Current Colorectal Cancer Reports</i> , 2009, 5, 171-178.	1.0	2
258	Analysis of <i>PTEN</i> , <i>BRAF</i> , and <i>EGFR</i> Status in Determining Benefit From Cetuximab Therapy in Wild-Type <i>KRAS</i> Metastatic Colon Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5924-5930.	0.8	645
259	Dendritic Cell-Derived Exosomes Promote Natural Killer Cell Activation and Proliferation: A Role for NKG2D Ligands and IL-15. <i>PLoS ONE</i> , 2009, 4, e4942.	1.1	352
260	Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma. <i>Cancer</i> , 2008, 112, 2733-2739.	2.0	133
261	The Critical Role of IL-15 in the Antitumor Effects Mediated by the Combination Therapy Imatinib and IL-2. <i>Journal of Immunology</i> , 2008, 180, 6477-6483.	0.4	44
262	Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: scientific background and the ongoing PETACC-8 trial. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 183-189.	1.1	25
263	Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer?. <i>Current Opinion in Oncology</i> , 2008, 20, 454-458.	1.1	15
264	Therapy-Induced Tumor Immunosurveillance Involves IFN-Producing Killer Dendritic Cells: Figure 1.. <i>Cancer Research</i> , 2007, 67, 851-853.	0.4	33
265	Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC). <i>Cancer</i> , 2007, 109, 1384-1390.	2.0	187
266	Hepatocellular Carcinoma (HCC): An Update. <i>Seminars in Oncology</i> , 2007, 34, S12-S20.	0.8	57
267	The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease. <i>Journal of Hepatology</i> , 2006, 44, 1175-1185.	1.8	50
268	A novel dendritic cell subset involved in tumor immunosurveillance. <i>Nature Medicine</i> , 2006, 12, 214-219.	15.2	377
269	Dendritic cell derived-exosomes: biology and clinical implementations. <i>Journal of Leukocyte Biology</i> , 2006, 80, 471-478.	1.5	117
270	Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines. <i>Journal of Immunology</i> , 2006, 176, 2722-2729.	0.4	192

#	ARTICLE	IF	CITATIONS
271	IL-2 production by dendritic cells is not critical for the activation of cognate and innate effectors in draining lymph nodes. <i>European Journal of Immunology</i> , 2005, 35, 2840-2850.	1.6	12
272	CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor- β dependent manner. <i>Journal of Experimental Medicine</i> , 2005, 202, 1075-1085.	4.2	806
273	The potential of exosomes in immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, 737-747.	1.4	42
274	The dialogue between natural killer cells and dendritic cells. <i>International Congress Series</i> , 2005, 1285, 169-176.	0.2	0
275	The potential of exosomes in immunotherapy of cancer. <i>Blood Cells, Molecules, and Diseases</i> , 2005, 35, 111-115.	0.6	37
276	Exosomes as Potent Cell-Free Peptide-Based Vaccine. II. Exosomes in CpG Adjuvants Efficiently Prime Naive Tc1 Lymphocytes Leading to Tumor Rejection. <i>Journal of Immunology</i> , 2004, 172, 2137-2146.	0.4	233
277	Exosome-based immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 234-239.	2.0	113
278	Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. <i>Journal of Clinical Investigation</i> , 2004, 114, 379-388.	3.9	248
279	Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. <i>Cancer</i> , 2003, 98, 2664-2670.	2.0	71
280	Anti-tumor necrosis factor-alpha therapy in severe alcoholic hepatitis: are large randomized trials still possible?. <i>Journal of Hepatology</i> , 2003, 38, 518-520.	1.8	24
281	Truth Survival in Clinical Research: An Evidence-Based Requiem?. <i>Annals of Internal Medicine</i> , 2002, 136, 888.	2.0	94
282	Polymorphonuclear neutrophils are a source of hepatocyte growth factor in patients with severe alcoholic hepatitis. <i>Journal of Hepatology</i> , 2002, 36, 342-348.	1.8	57
283	Ethanol-induced inhibition of cytokine release and protein degranulation in human neutrophils. <i>Journal of Leukocyte Biology</i> , 2002, 72, 1142-7.	1.5	28
284	Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids. <i>Journal of Hepatology</i> , 2000, 32, 579-586.	1.8	114
285	CYTOKINES AND ALCOHOLIC HEPATITIS. <i>Alcoholism: Clinical and Experimental Research</i> , 1998, 22, 760-762.	1.4	1
286	Raised plasma soluble Fas and Fas-ligand in alcoholic liver disease. <i>Lancet, The</i> , 1998, 351, 1930-1931.	6.3	83
287	Hepatic Arterial Infusion Chemotherapy With Folfirinox or Oxaliplatin Alone in Metastatic Colorectal Cancer. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1